StockNews.AI

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT

StockNews.AI • 21 hours

CORT
High Materiality10/10

Information

NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves...

Original source

AI Summary

Pomerantz LLP is investigating Corcept Therapeutics for potential securities fraud following an FDA Complete Response Letter regarding relacorilant. The news led to a dramatic 50.42% stock price drop, reflecting significant investor concern about the company's future prospects and potential legal ramifications.

Sentiment Rationale

Corcept’s stock has already reacted sharply to negative news. Historical cases show significant declines often lead to prolonged recovery periods due to investor sentiment and legal costs.

Trading Thesis

Invest in CORT with caution; regulatory and legal risks loom in the short term.

Market-Moving

  • Regulatory updates regarding relacorilant could change market sentiment substantially.
  • Ongoing investigations may lead to increased legal costs or settlements for Corcept.
  • Public perception of Corcept's management and transparency is critical for recovery.

Key Facts

  • Pomerantz LLP is investigating Corcept for potential securities fraud.
  • The FDA issued a Complete Response Letter for relacorilant's NDA.
  • Corcept's stock plummeted 50.42% following the FDA's announcement.
  • Investors are advised to join the class action investigation.
  • Additional evidence of relacorilant's effectiveness is required by the FDA.

Companies Mentioned

  • Corcept Therapeutics Incorporated (CORT): CORT is under investigation for securities fraud, affecting its stock outlook.
  • Pomerantz LLP (N/A): Investigating claims could complicate Corcept's legal standing and increase liabilities.

Corporate Developments

The news fits under Corporate Developments due to ongoing scrutiny on legal practices. Regulatory failures may affect investor trust and financial performance moving forward.

Investor Alert: Pomerantz Law Firm Investigates Corcept Therapeutics (CORT)

NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) — Pomerantz LLP has announced an investigation on behalf of investors of Corcept Therapeutics Incorporated (NASDAQ: CORT). This inquiry aims to determine if Corcept and certain officers and directors have engaged in securities fraud or other illegal business practices. Investors seeking more information can contact Danielle Peyton at newaction@pomlaw.com or call 646-581-9980, ext. 7980.

Recent Developments Impacting Corcept's Stock

On December 31, 2025, Corcept released a press announcement detailing that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) concerning the New Drug Application (NDA) for relacorilant. This drug is intended for treating patients with hypertension secondary to hypercortisolism.

The company stated that the FDA recognized the success of Corcept’s pivotal GRACE trial in achieving its primary endpoint. However, the agency concluded that additional evidence of effectiveness is necessary for a favorable benefit-risk assessment of relacorilant.

Impact on Corcept's Stock Performance

Following this announcement, shares of Corcept (CORT) experienced a significant decline. The stock price plummeted by $35.40 per share, equating to a 50.42% drop, and closed at $34.80 on December 31, 2025.

Pomerantz LLP: A Leader in Securities Class Litigation

Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with offices in major cities including New York, Chicago, Los Angeles, London, Paris, and Tel Aviv. Founded by the late Abraham L. Pomerantz, who is often referred to as the dean of the class action bar, the firm has pioneered the field of securities class actions and has a rich history of advocating for investors' rights.

Over the past 85 years, Pomerantz has successfully recovered numerous multimillion-dollar damages for victims of securities fraud and corporate misconduct. For more information, visit www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

For inquiries, contact Danielle Peyton at dpeyton@pomlaw.com or call 646-581-9980, ext. 7980.

Related News